The TR(ACE) Assay is a quantitative in vitro diagnostic test run on the TR(ACE) Instrument intended for the measurement of high molecular weight human DNA from plasma as an aid to monitoring disease progression or response to therapy or recurrent or residual disease.

This study is to establish the clinical performance of the TR(ACE) Assay. Deltas of serial TR(ACE) Assay measurements will be compared to the standard of care physician clinical assessment and RECIST 1.1 criteria evaluation relative to the previous visit. Significant changes in serial TR(ACE) Assay measurements are hypothesized to correlate with disease progression or response.

Inclusion Criteria:

• Non-small cell lung: Male or Female Adult patient >= 21 years old
• Breast only: Female Adult patient >= 21 years old
• Previously diagnosed with one of the following cancers:

Breast or Non-small Cell Lung

• Cancer has progressed to at least Stage III or higher for lung cancer or,
• Cancer has progressed to stage IV (metastatic) breast cancer
• Participating in standard of care cancer therapy requiring frequent treatments, typically intravenous chemotherapy visits (or as determined by the standard of care for the particular cancer assessed), of a minimum of three (3) treatment visits planned in 9 months from date of enrollment where a clinical assessment will be conducted

Exclusion Criteria:

• Physician assessment that obtaining two extra whole blood specimens with minimum volume of 5 mL per treatment visit is contraindicated
• Stage I and II Non-small Cell Lung Cancer
• Stage I through III breast cancer
• Pregnant or planning to become pregnant during the course of the study
• Unable to obtain informed consent from subject or their legal representative
• Life expectancy is less than 9 months
• Presence of one or more of the following other chronic diseases
• Another type of cancer except for non-melanomatous skin tumors
• Autoimmune disease requiring DMARDS or Biologics
• Infectious disease requiring prolonged intravenous antibiotics or hospitalization
• Renal disease specifically those in End Stage Renal Failure
• Recent (< 3 weeks) major trauma or major surgical procedure(s) or radiation therapy prior to enrollment in the study
• Recent (< 2 months) major occlusive arterial event such as MI or CVA prior to enrollment in the study

Previously diagnosed non-small cell lung cancer subjects undergoing standard of care treatment Previously diagnosed breast cancer subjects undergoing standard of care treatment

Following direct de novo submission, data will be summarized in decision summary and package insert